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Ventricular arrhythmias in patients with nonischemic car-
diomyopathy (NICM) often affect patients’ prognosis. Ven-
tricular tachycardias (VTs) arising from the electrical scar
area in hearts of NICM patients could become targets for
radiofrequency catheter ablation (RFCA) therapy.1–3 How-
ever, the efﬁcacy of RFCA using the endocardial approach is
limited because of the deeper localization of the electrical
scar from the intramural to the epicardial side.1–3 Recently,
combined endocardial and epicardial ablation has been used
to improve the RFCA outcomes for VT in patients with
NICM. However, elimination of the VTs is still challeng-
ing,1–6 especially in patients with hypertrophic cardiomyop-
athy (HCM).7,8 In this case report, we evaluated the
pathologic features after combined epicardial and endocar-
dial ablation in a postmortem heart from a patient with HCM.Case report
The patient was a 73-year-old man who was diagnosed with
HCM at the age of 63 years. The left ventricular chamber
showed progressive dilation with contractile dysfunction
from the age of 67, and the heart was thought to be in an
advanced dilated form. In spite of the administration of
β-blocker and amiodarone as concomitant medical therapy
for heart failure and nonsustained VT, the effect was
insufﬁcient, and he was implanted with cardiac resynchro-
nization therapy with deﬁbrillator.KEYWORDS Hypertrophic cardiomyopathy; Pathology; Ablation; Ventricular
tachycardia
ABBREVIATIONS ECG ¼ electrocardiogram; HCM ¼ hypertrophic
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).The patient was admitted to our hospital because of
repetitive drug-resistant VT at the age of 73 years. Echo-
cardiography revealed an aneurysm at the apical portion of
the left ventricle (LV), which was accompanied by severe
LV dysfunction (left ventricular ejection fraction 21%) and
asymmetric septal hypertrophy. On the day of admission, the
patient presented with VT storm, was intubated, and under-
went assisted cardiopulmonary support because the VTs
were resistant to antiarrhythmic drugs and hemodynamically
unstable. Coronary angiography showed no signiﬁcant
stenosis in coronary arteries. Under intravenous β-blocker
administration, RFCA was performed to control the
VT storm.Electrophysiological examination and
ablation procedure
Most of the clinical VTs in the 12-lead electrocardiogram
(ECG) showed a right bundle branch block pattern with
slowed initial precordial QRS activation (Figure 1A). We
performed RFCA using the epicardial and endocardial
approach because the origins of some VTs were thought to
be located on the epicardial side based on the 12-lead ECG
ﬁndings.
Steerable catheters were inserted from the right femoral
vein and placed in the coronary sinus and the ventricle of
interest. The LV endocardium was accessed using the trans-
septal approach. Pericardial access was obtained through a
subxiphoid and anterior puncture under ﬂuoroscopic guide.
We used a 3.5-mm open-irrigatedtip ablation catheter,
Thermocool (Biosense Webster, Johnson & Johnson, Dia-
mond Bar, CA), which was also used for mapping. Bipolar
voltage maps of the endocardium and epicardium were
constructed during sinus rhythm. Arrhythmogenic areas,
indicated by low-voltage zones (LVZs), which were deﬁned
as o1.5 mV at the endocardium and o1.0 mV at the
epicardium, were mainly located on the lateral to posterior
wall in the LV endocardium and throughout the entire LV in
the epicardium (Figure 2A and B).pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.04.003
KEY TEACHING POINTS
 Lesion depth created by radiofrequency catheter
ablation is smaller on the epicardium with adipose
tissue than on the endocardium.
 It seems to be difﬁcult to create transmural lesions
even by combined epicardial and endocardial
ablation, especially in patients with thickened
ventricular walls.
 Some approaches such as needle, bipolar, and
transcoronary ethanol ablation may be more
effective to create transmural lesions.
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pacing, although clinically documented VTs did not appear
(Figure 1B). We performed substrate-based RFCA, which
targeted the LVZs and abnormal electrograms such as
delayed potentials, fragmented potentials, and/or double
potentials in the endocardium and epicardium. Open-
irrigated radiofrequency (RF) current was delivered for up
to 60 seconds in power-controlled mode as follows: power
30–45 W and irrigation 17–30 mL/min. Total application
time of RFCA was about 86 minutes.Clinical course after ablation
A VT that was not induced in the electrophysiological
study emerged after the RFCA session. The VT was
clinically controlled by antiarrhythmic drugs (amiodar-
one, nifekalant, and lidocaine). The patient, however, died
from deterioration of heart failure 49 days after the
procedure. A postmortem examination of the heart was
performed.Figure 1 A: A representative 12-lead electrocardiogram of clinical ventricular ta
right superior axis. VT cycle length is 330 ms, with a widened QRS duration and a s
origin. B: Six VTs induced by right ventricular pacing.Postmortem gross pathologic ﬁndings
The epicardium of the heart was mildly adhered to the
pericardium around the apex of the LV with a thin ﬁbrinous
exudate, and this was thought to be an inﬂammatory reaction
after the epicardial ablation procedure. There was no increase
in pericardial ﬂuid volume.
The heart was signiﬁcantly enlarged and weighed 820 g.
There was rich epicardial fat attached in the atrioventricular
and interventricular groove, and it was also widely distrib-
uted in the free wall of the LV that roughly corresponded to
the voltage map ﬁndings (Figure 2B and C). On the LV
epicardial surface, RFCA results showed discolored spotty
lesions around the LV apex.
All 4 chambers of the heart were dilated along the long
axis section through the heart. The LV wall showed
asymmetric hypertrophy as follows: 27 mm thickness in
the ventricular septum, and the papillary muscle was also
hypertrophied (Figure 3A). The LV apical wall was thinning
with complex endocardial trabeculation, and it showed
aneurysmal dilation that was thought to be an arrhythmo-
genic source. The ablated lesions from the endocardial
approach were observed as blackish spots mainly located
in and at the border of the aneurysmal lesion. All coronary
arteries showed no arteriosclerotic stenosis.
Ablated lesion beneath the epicardium and
endocardium
Figure 3 shows a cross section of the ablated lesions at the
border of the LV aneurysm, where both the epicardial and
endocardial approach ablation lesions were assessed. The
endocardial lesions were clearly deﬁned and were deeper
than the epicardial lesions. The cloudy discolored areas were
necrotic tissue caused by RF energy, and the adjacent black-
colored areas were lesions with hemorrhage caused bychycardia (VT). The VT exhibited a right bundle branch block pattern and a
lowed initial precordial QRS activation, indicating that the VT is of epicardial
Figure 2 Comparison between the macroscopic view of the epicardial surface and the electroanatomic voltage map. A: Epicardial voltage map of the left
ventricle (LV) from the left lateral cranial direction. Blue, green, yellow, and red areas indicate the progressively low-voltage zones (LVZs), deﬁned aso1.0 mV.
Brown dots indicate ablation points. Pink dots indicate abnormal electrocardiograms including the delayed potentials, fragmented potentials, and double
potentials. B: Endocardial voltage map of the LV from the left lateral cranial direction. Brown dots indicate ablation points. The LVZ, deﬁned aso1.5 mV, is
located lateral to the posterior wall in the LV endocardium. C: The macroscopic view of the LV corresponds to Figure 2A before ﬁxation in formalin. Rich
adipose tissue covers the epicardial surface. The opaque discolored yellow area encircled by the dotted line indicates the ablation lesion. The location of the fatty
tissue and uncovered myocardium roughly corresponds to the ﬁndings of epicardial voltage map. The white line labeled b indicates the cutting line in Figure 3B.
Microscopic ﬁndings at lines a, c, and d are shown in the Supplemental Figure (available online). RV ¼ right ventricle.
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On the epicardial side, the LV apex around the ablated
lesions was diffusely covered by fatty tissue, and its thick-
ness was up to 5 mm. The fatty layer was transmurally
discolored; however, the change of the myocardium beneath
the epicardial fat was limited (Figure 3B).Figure 3C shows the identical histologic sections to
Figure 3B, and the original pathologic ﬁbrosis resulting
from HCM diffusely extended mainly in the center and
epicardial side of the LV wall. The ablation scar reached a
depth of 6 mm from the endocardial surface at its deepest
site, whereas the ablation scar from the epicardial surface
Figure 3 Cross sections of the ablated lesions, post formalin ﬁxation. A: Macroscopic endocardial overview of the left ventricle (LV) in the 4-chamber cut.
The ventricular septum (VS) shows asymmetric hypertrophy, and the apex shows aneurysmal dilation with the wall thinning. Ablated lesions (white and yellow
arrowheads) are located in the dilated lesion. B: Cross-sectional macroscopic ﬁnding at the white line in Figure 2C. Yellow arrowheads indicate ablated lesions
in epicardial fat, which is approximately 2–4 mm thick. Blackish areas are observed at deeper sites in the endocardium. C:Microscopic ﬁndings from Figure 3B
with Masson’s trichrome stain. Irregular ﬁbrotic layers that are originally caused by hypertrophic cardiomyopathy (HCM) are mainly distributed in the center of
the LV wall (black arrows). The yellow dotted line represents an ablation lesion from the endocardium. Within this area, hemorrhagic necrosis is observed. The
red line represents an ablation lesion from the epicardium, and the ablation scar reached a maximum depth of 6 mm. On the epicardium, the maximum depth of
the ablation scar was only 2 mm beyond the epicardial adipose tissue. Myocardium that escaped the ablation energy was visible between the epicardial and
endocardial ablation lesions. CS ¼ coronary sinus, LA ¼ left atrium, TV ¼ tricuspid valve, RV ¼ right ventricle, MV ¼ mitral valve, END ¼ endocardium,
EPI ¼ epicardium.
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epicardial and endocardial ablated lesions, there was approx-
imately 1.5 mm of viable myocardial tissue with pathologic
ﬁbrosis that escaped the RF energy at the border of the
aneurysmal wall, and there were no obvious transmural
ablation lesions. In addition, the spared viable myocardium
was especially noted on the top of the trabeculi or bridging
the myocardial bundles, despite that the deeper sites were
ablated.
The peripheral area of the ablated sites was replaced with
mature ﬁbrous tissue, but the remaining necrotic tissue and
hemorrhagic area were still observed at the core of the
ablated sites. This histologic discrepancy in the relatively
long phase after RF (approximately 6 weeks) may be
attributed to the prolonged wound healing process of the
intramural hemorrhage and small vessel injuries.9Discussion
This case provided us with important information by the
analysis of pathologic changes after combined epicardial and
endocardial ablation with open-irrigated catheter for the ﬁrsttime in a human heart. We focused on the 2 major ﬁndings in
this heart, as described below.
The ﬁnding of voltage maps with larger LVZ on the
epicardium than that on the endocardium was roughly in
accordance with the histopathology of the heart (Figure 3C
and Supplemental Figure, available online). We assumed
that the LVZ on the epicardium, however, indicated not only
original pathologic ﬁbrosis but also the fat on the epicar-
dium. The pathologic evaluation showed that transmural
ablation could not be achieved in this case. Even though new
strategies such as local abnormal ventricular activity ablation
or homogenization of the scar area in electroanatomic
mapping have been developed for unstable hemodynamic
VTs, efﬁcacy of epicardial ablation is limited in cases like
this, which might be attributed to residual arrhythmic
substrate, especially in NICM.10,11 The saline irrigation
catheter produces deeper and larger ablation lesions in vivo
compared with a non–irrigation catheter.12 However, despite
the use of open-irrigated epicardial ablation, transmural
ablation lesions are found in only 55% of cases.13
Some studies reported that the lesions made by epicardial
ablations were affected by the rich adipose tissues in the
Heart Rhythm Case Reports, Vol 1, No 5, September 2015314epicardium.14 The degree of inﬂuence of the epicardial fat
thickness on the RF delivery is controversial. Van Huls van
Taxis et al15 reported the clear cut-off of thickness threshold
to impair RF delivery as 7 mm. On the other hand, Hong
et al16 reported that the epicardial fat could severely limit the
lesion depth created by RF energy, even in the case with the
epicardial fat thickness of 2 mm.16 In this case, ablated scars
were not reached deeper from epicardial site than those from
endocardial site because of rich adipose tissues. The
impaired RF delivery, which was demonstrated by limited
ablation lesions from the epicardial surface, might also result
from the catheter instability, weak contact force, and/or
inadequate RF power on the epicardium. The VT recurrence
after RFCA might be also due to inability to map and/or
identify critical sites of VTs. We retrospectively examined
the electrogram response (R wave reduction of the electro-
gram) by RF delivery in this case, and compared it between
RF delivery from the epicardium and from the endocardium.
In total, the number of RF applications from the endocar-
dium was 128 and that from the epicardium was 109. The
mean percentage of the R wave reduction by RF energy was
signiﬁcantly lower in the epicardium than in the endocar-
dium (59%  25% vs 69%  25%; P ¼ .009). In order to
achieve transmural lesions, other approaches such as needle,
bipolar, and transcoronary ethanol ablation may be neces-
sary, especially in cases with thickened ventricular wall, as in
this HCM patient.17–19
In this case, we could control VTs clinically with concom-
itant use of antiarrhythmic drugs. Therefore, combined epi-
cardial and endocardial ablation was useful to modify the
substrate for VTs in spite of the residual viable myocardial
tissue between the endocardium and epicardium in this case.
Conclusion
To our knowledge, this is the ﬁrst case that shows important
pathologic information after combined epicardial and endo-
cardial ablation using an open-irrigated catheter in a human
heart. This pathologic report showed the limitation of the
epicardial RFCA to deliver sufﬁcient RF energy to the
myocardium beyond the epicardial adipose tissue, which
resulted in residual arrhythmogenic substrate even after
combined epicardial and endocardial RFCA.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrcr.2015.
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